Rate My Professor Ryan Duchatel

Dr. Ryan Duchatel is a Cancer Institute NSW Fellow and postdoctoral researcher in the School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, at the University of Newcastle, Australia. He earned his PhD in Experimental Pharmacology from the University of Newcastle in 2018, following Bachelor degrees in Biomedical Sciences with Honours from the same institution. As a member of the Cancer Signalling Research Group led by Dr. Matthew Dun at the Hunter Medical Research Institute, Duchatel specializes in pediatric high-grade gliomas, particularly diffuse intrinsic pontine glioma (DIPG). His research encompasses in vitro neurosphere modeling, high-resolution quantitative proteomics, identification of compensatory signaling pathways, and development of novel therapeutic strategies targeting PI3K/mTOR dependencies, mitochondrial protease ClpP, and combination therapies like ONC201 with paxalisib.

Duchatel's contributions are recognized through awards such as the Cancer Institute NSW Career Development Fellowship (2025–2028) and the ChadTough Defeat DIPG Fellowship (2023–2025). He holds key roles including Deputy Chair of the Hunter Cancer Research Alliance Future Leaders Group and serves on the scientific advisory committee of the Hunter Cancer Biobank. Notable publications include "PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma" (Journal of Clinical Investigation, 2024), "ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma" (Cancer Research, 2023), "Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies" (Oncogene, 2022), "Blockade of ROS production inhibits oncogenic signaling in acute myeloid leukemia and amplifies response to precision therapies" (Science Signaling, 2023), and "Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways" (Cancer Discovery, 2023). These works underscore his impact on advancing precision medicine for aggressive pediatric cancers.